Trials / Completed
CompletedNCT03613168
Trastuzumab in HER2-positive Biliary Tract Cancer
The Pilot Study of Trastuzumab in Combination With Gemcitabine Plus Cisplatin for HER2-positive Biliary Tract Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Changhoon Yoo · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Trastuzumab plus gemcitabine/cisplatin |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2020-11-01
- Completion
- 2021-01-04
- First posted
- 2018-08-02
- Last updated
- 2021-01-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03613168. Inclusion in this directory is not an endorsement.